Drug Free Solution, Inc. (DSOL)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2020 | 2019 | 2017 | 2013 |
|---|---|---|---|---|
| Operating Cash Flow | -382.9 Thousand | -401.5 Thousand | -22.25 Thousand | -692.31 Thousand |
| Net Income | -1.4 Million | -1.45 Million | -67.09 Thousand | -755.86 Thousand |
| Depreciation & Amortization | 12.34 Thousand | 5966.00 | 8028.00 | 972.00 |
| Deferred income taxes | - | - | - | - |
| Stock-based compensation | - | - | - | - |
| Change in working capital | 77 Thousand | - | -195.00 | 62.58 Thousand |
| Other non-cash items | 944.72 Thousand | 1.05 Million | 53.05 Thousand | -18.91 Thousand |
| Investing Cash Flow | -36.83 Thousand | -18.8 Thousand | - | - |
| Investments in PPE | -36.83 Thousand | -18.8 Thousand | - | - |
| Acquisitions | - | - | - | - |
| Investment purchases | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - |
| Other Investing Activities | - | - | - | - |
| Financing Cash Flow | 429.7 Thousand | 422.82 Thousand | 22.25 Thousand | 685.05 Thousand |
| Debt repayment | - | - | - | - |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | - | - | - | - |
| Common Stock Issuance | 429.7 Thousand | 422.82 Thousand | 22.25 Thousand | 685.05 Thousand |
| Other Financing Activities | - | - | - | 685.05 |
| Accounts receivables | - | - | - | - |
| Accounts payables | 15 Thousand | - | - | 20.85 Thousand |
| Inventory | - | - | - | - |
| Other working capital | 62 Thousand | - | -195.00 | 41.73 Thousand |
| Cash at beginning of period | 2526.00 | - | 8157.00 | 15.41 Thousand |
| Cash at end of period | 12.5 Thousand | 2526.00 | 8157.00 | 8157.00 |
| Capital Expenditure | -36.83 Thousand | -18.8 Thousand | - | - |
| Effect of forex changes on cash | - | - | - | - |
| Net cash flow / Change in cash | 9976.00 | 2526.00 | - | -7258.00 |
| Free Cash Flow | -419.73 Thousand | -420.3 Thousand | -22.25 Thousand | -692.31 Thousand |
| Breakdown | 2019 FY | 2018 FY | 2016 FY | 2013 Q3 | 2013 Q2 | 2013 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.4 Million | -1.45 Million | -67.09 Thousand | -120.35 | -124.91 | -50.49 |
| Depreciation & Amortization | 12.34 Thousand | 5966.00 | 8028.00 | 3.50 | 1.50 | 0.24 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 77 Thousand | - | -195.00 | - | -4.03 | -37.70 |
| Other non-cash items | 944.72 Thousand | 1.05 Million | 53.05 Thousand | 14.34 | 69.71 | 43.02 |
| Investing Cash Flow | -36.83 Thousand | -18.8 Thousand | - | - | -40.00 | - |
| Investments in PPE | -36.83 Thousand | -18.8 Thousand | - | - | -36.00 | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | -4.00 | - |
| Financing Cash Flow | 429.7 Thousand | 422.82 Thousand | 22.25 Thousand | 109.03 | 96.60 | 38.50 |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 429.7 Thousand | 422.82 Thousand | 22.25 Thousand | - | - | - |
| Other Financing Activities | - | - | - | 109.03 | 96.60 | 38.50 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 15 Thousand | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 62 Thousand | - | -195.00 | - | -4.03 | -37.70 |
| Cash at beginning of period | 2526.00 | - | 8157.00 | 0.60 | 1.73 | 8.16 |
| Cash at end of period | 12.5 Thousand | 2526.00 | 8157.00 | 7.12 | 0.60 | 1.73 |
| Capital Expenditure | -36.83 Thousand | -18.8 Thousand | - | - | -36.00 | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 9976.00 | 2526.00 | - | 6.52 | -1.13 | -6.43 |
| Free Cash Flow | -419.73 Thousand | -420.3 Thousand | -22.25 Thousand | -102.51 | -93.73 | -44.93 |
214420
DGNG
OMID
ATLANTAA
III
STHI